Should I buy or sell Amphastar Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks .

What is Amphastar Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $63.00 to $71.00. On average, they expect the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts .

How have AMPH shares performed in 2023?

Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH stock has increased by 96.6% and is now trading at $55.10. View the best growth stocks for 2023 here .

Are investors shorting Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,890,000 shares, an increase of 15.6% from the October 31st total of 2,500,000 shares. Based on an average daily trading volume, of 450,200 shares, the short-interest ratio is presently 6.4 days. Currently, 8.1% of the company's shares are sold short. View Amphastar Pharmaceuticals' Short Interest .

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our AMPH earnings forecast .

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings data on Monday, November, 8th. The company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The business had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 26.68% and a net margin of 22.50%. During the same period last year, the firm posted $0.09 EPS.

What ETFs hold Amphastar Pharmaceuticals' stock?

ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , Innovator IBD 50 ETF (FFTY) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) , ETC 6 Meridian Small Cap Equity ETF (SIXS) , Invesco S&P SmallCap Health Care ETF (PSCH) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ERShares NextGen Entrepreneurs ETF (ERSX) .

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com . Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA) , Gilead Sciences (GILD) , Amicus Therapeutics (FOLD) , Exelixis (EXEL) , CNX Resources (CNX) , Immunomedics (IMMU) , AbbVie (ABBV) , Cellectis (CLLS) , Clovis Oncology (CLVS) and Galectin Therapeutics (GALT) .

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (7.18%), Fuller & Thaler Asset Management Inc. (2.66%), Northern Trust Corp (1.17%), Morgan Stanley (1.17%), Jacobs Levy Equity Management Inc. (1.16%) and Invesco Ltd. (0.86%). Insiders that own company stock include Diane G Gerst , Floyd F Petersen , Howard Lee , Jack Y Zhang , Michael A Zasloff , Richard K Prins , Richard Koo , Rong Zhou , William J Peters, William J Peters and Yakob Liawatidewi . View institutional ownership trends .

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Amphastar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMPH)

$55.14

+0.73 (+1.34%)

(As of 12:21 PM ET)

Compare

Today's Range: $54.43
▼
$55.95
50-Day Range: $44.49
▼
$57.52
52-Week Range: $27.58
▼
$67.66

Volume: 135,339 shs
Average Volume: 391,269 shs
Market Capitalization: $2.64 billion

P/E Ratio: 21.54
Dividend Yield: N/A
Price Target: $68.00

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 23.4% Upside
$68.00 Price Target
Short Interest: Bearish
8.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.21
Upright™ Environmental Score
News Sentiment: 0.52
Based on 4 Articles This Week
Insider Trading: Selling Shares
$3.67 M Sold Last Quarter
Proj. Earnings Growth: 17.87%
From $2.91 to $3.43 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

91st out of 949 stocks

Pharmaceutical Preparations Industry

30th out of 440 stocks

2.3

Analyst's Opinion

Consensus Rating
Amphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $68.00, Amphastar Pharmaceuticals has a forecasted upside of 23.4% from its current price of $55.10.
Amount of Analyst Coverage
Amphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.10% of the float of Amphastar Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Amphastar Pharmaceuticals has recently increased by 15.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Amphastar Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amphastar Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.
Environmental Sustainability
The Environmental Impact score for Amphastar Pharmaceuticals is -2.21.

2.5

News and Social Media Coverage

News Sentiment
Amphastar Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
9 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
MarketBeat Follows
11 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,674,930.00 in company stock.
Percentage Held by Insiders
27.80% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Amphastar Pharmaceuticals are expected to grow by 17.87% in the coming year, from $2.91 to $3.43 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amphastar Pharmaceuticals is 21.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.81.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amphastar Pharmaceuticals is 21.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.29.
Price to Earnings Growth Ratio
Amphastar Pharmaceuticals has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Amphastar Pharmaceuticals has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMPH Stock News Headlines

November 27, 2023 | benzinga.com

Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry

November 24, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Delivered A Better ROE Than Its Industry

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 21, 2023 | americanbankingnews.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins Sells 4,000 Shares

November 21, 2023 | americanbankingnews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by StockNews.com

November 21, 2023 | finance.yahoo.com

Insider Sell Alert: Director Richard Prins Sells 4,000 Shares of Amphastar Pharmaceuticals Inc ...

November 20, 2023 | finanznachrichten.de

Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 19, 2023 | americanbankingnews.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update

November 19, 2023 | americanbankingnews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Bank of America

November 18, 2023 | msn.com

B of A Securities Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Neutral Recommendation

November 17, 2023 | msn.com

BofA starts Amphastar at neutral; cites high valuation, Baqsimi prospects

November 17, 2023 | realmoney.thestreet.com

Amphastar initiated with a Neutral at BofA after 97% year-to-date rally

November 17, 2023 | finance.yahoo.com

Insider Sell: CFO William Peters Sells Shares of Amphastar Pharmaceuticals Inc

November 16, 2023 | finance.yahoo.com

Insider Sell: Director Richard Prins Sells 5,000 Shares of Amphastar Pharmaceuticals Inc (AMPH)

November 13, 2023 | finance.yahoo.com

Wall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest?

November 10, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade

November 10, 2023 | markets.businessinsider.com

Needham Keeps Their Hold Rating on Amphastar Pharmaceuticals (AMPH)

November 9, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Q3 2023 Amphastar Pharmaceuticals Inc Earnings Call

November 9, 2023 | msn.com

Amphastar Pharmaceuticals Non-GAAP EPS of $1.15 beats by $0.46, revenue of $180.6M beats by $6.8M

November 8, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

November 7, 2023 | msn.com

Amphastar Pharmaceuticals Q3 2023 Earnings Preview

November 4, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals' (NASDAQ:AMPH) 42% YoY earnings expansion surpassed the shareholder returns over the past three years

November 1, 2023 | finance.yahoo.com

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

October 31, 2023 | morningstar.com

Amphastar Pharmaceuticals Inc AMPH

See More Headlines

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMPH
CUSIP: N/A
CIK: 1297184
Web: www.amphastar.com
Phone: (909) 980-9484
Fax: 909-980-8296
Employees: 1,615
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $68.00
High Stock Price Target: $71.00
Low Stock Price Target: $63.00
Potential Upside/Downside: +25.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.56
Trailing P/E Ratio: 21.25
Forward P/E Ratio: 18.70
P/E Growth: 0.86
Net Income: $91.39 million
Net Margins: 22.50%
Pretax Margin: 28.48%
Return on Equity: 26.68%
Return on Assets: 13.60%

Debt

Debt-to-Equity Ratio: 1.07
Current Ratio: 2.11
Quick Ratio: 1.68

Sales & Book Value

Annual Sales: $498.99 million
Price / Sales: 5.22
Cash Flow: $2.26 per share
Price / Cash Flow: 24.05
Book Value: $10.94 per share
Price / Book: 4.97

Miscellaneous

Outstanding Shares: 47,910,000
Free Float: 34,589,000
Market Cap: $2.61 billion
Optionable: Optionable
Beta: 0.87

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Ziping Luo Ph.D. (Age 73)
Chairman of the Board, Chief Scientist & COO
Comp: $1.53M
Dr. Yongfeng Zhang Ph.D. (Age 76)
Co-Founder, President, CEO, Chief Scientific Officer & Director
Comp: $2.13M
Mr. William J. Peters M.B.A. (Age 55)
CFO, Executive VP of Finance, Treasurer & Director
Comp: $1.12M
Mr. Jacob Liawatidewi M.B.A. (Age 49)
Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Comp: $794.15k
Mr. Rong Zhou M.S. (Age 64)
Senior Executive Vice President of Production
Comp: $835.05k
Dan Dischner M.B.A.
Vice President of Human Resources & Corporate Communication
Tony Marrs M.B.A.
M.P.H., Senior VP of Regulatory Affairs & Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings or view top-rated stocks.
What is Amphastar Pharmaceuticals' stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $63.00 to $71.00. On average, they expect the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts.
How have AMPH shares performed in 2023?: Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH stock has increased by 96.6% and is now trading at $55.10.
View the best growth stocks for 2023 here.
Are investors shorting Amphastar Pharmaceuticals?: Amphastar Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,890,000 shares, an increase of 15.6% from the October 31st total of 2,500,000 shares. Based on an average daily trading volume, of 450,200 shares, the short-interest ratio is presently 6.4 days. Currently, 8.1% of the company's shares are sold short.
View Amphastar Pharmaceuticals' Short Interest.
When is Amphastar Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our AMPH earnings forecast.
How were Amphastar Pharmaceuticals' earnings last quarter?: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings data on Monday, November, 8th. The company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The business had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 26.68% and a net margin of 22.50%. During the same period last year, the firm posted $0.09 EPS.

What ETFs hold Amphastar Pharmaceuticals' stock?: ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Innovator IBD 50 ETF (FFTY), Janus Henderson Small Cap Growth Alpha ETF (JSML), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ERShares NextGen Entrepreneurs ETF (ERSX).
What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?: 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.
What other stocks do shareholders of Amphastar Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).
Who are Amphastar Pharmaceuticals' major shareholders?: Amphastar Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (7.18%), Fuller & Thaler Asset Management Inc. (2.66%), Northern Trust Corp (1.17%), Morgan Stanley (1.17%), Jacobs Levy Equity Management Inc. (1.16%) and Invesco Ltd. (0.86%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends.
How do I buy shares of Amphastar Pharmaceuticals?: Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial